SKAI: Talking with parents about human papillomavirus (HPV) vaccination

This recently published conversation guide aims to help immunisation providers engage confidently with parents and carers about the importance of timely human papillomavirus (HPV) vaccination.

Sharing Knowledge About Immunisation (SKAI): Talking with parents about human papillomavirus (HPV) vaccination 

To learn more about HPV, visit MVEC: HPV. 


TGA: 2026 Seasonal Influenza Vaccines

On 4 March, the Therapeutic Goods Administration (TGA) published its 2026 Seasonal Influenza Vaccines report. 

The report covers the 2026 seasonal influenza vaccines, with information on vaccines by age group, vaccine ingredients and co-administration. 

For more information, visit एमवीईसी: इन्फ्लुएंजा.


ATAGI: Statement on the administration of seasonal influenza vaccines in 2026

On 27 February, the national Department of Health and Aged Care released the ATAGI statement on the administration of seasonal influenza vaccines in 2026.

Influenza vaccines are recommended annually and are funded on the National Immunisation Program (NIP) for:

  • children aged 6 months to less than 5 years 
  • all adults aged 65 years and older 
  • specific populations aged 5 to 64 years who are at greatest risk of developing complications from influenza infection (including pregnant women, First Nations people, and those with certain medical risk factors). 

For more details, refer to ATAGI’s full statement, and MVEC’s influenza reference page which has been updated for the 2026 influenza season. 


The Guardian: FDA reverses course and will review Moderna’s mRNA-based flu vaccine

Following backlash after it initially refused to review Moderna’s mRNA influenza vaccine, the US Food and Drug Administration (FDA) will now review the vaccine.

Moderna submitted an application for the FDA to approve the new product in December 2025. Other countries, including Australia, accepted the vaccine for review. The FDA’s initial refusal to review the vaccine sparked concerns about the influence of the current administration.

Read the full article at The Guardian: FDA reverses course and will review Moderna’s mRNA-based flu vaccine.


एमवीईसी के बारे में

मेलबोर्न वैक्सीन एजुकेशन सेंटर (एमवीईसी) एक शैक्षिक वेबसाइट है, जिसे स्वास्थ्य सेवा पेशेवरों और जनता के सदस्यों दोनों के लिए अद्यतित टीकाकरण जानकारी प्रदान करने के उद्देश्य से विकसित किया गया है। हम मर्डोक चिल्ड्रन्स रिसर्च इंस्टीट्यूट (MCRI), एक शोध संगठन पर आधारित हैं, और SAEFVIC (समुदाय में टीकाकरण के बाद प्रतिकूल घटनाओं की निगरानी), विक्टोरियन वैक्सीन सुरक्षा सेवा से संबद्ध हैं।